文献速递神经肿瘤小儿神经外科与脑积水

儿童型丘脑胶质瘤的DNA甲基化特征与EGFR改变

A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
PubMed 文献 · Neuro Oncol · 2021-01-01

研究分析58例儿童型恶性胶质瘤的表观遗传学特征,发现EGFR扩增占27%,可测序肿瘤中EGFR突变或插入占67%,部分伴H3 K27M突变;所有肿瘤均显示H3K27me3缺失,EGFR抑制可能为潜在治疗策略。

要点

  • 儿童型丘脑胶质瘤具有独特的DNA甲基化谱和H3K27me3缺失。
  • EGFR改变常见,包括扩增和突变/插入,可作为潜在治疗靶点。
  • 肿瘤可位于双侧或单侧丘脑及其他中线部位,不限于双丘脑。

核心结论

  • 儿童型恶性胶质瘤中存在一个以EGFR改变为特征的独特分子亚类,与双丘脑胶质瘤重叠但谱系更广。
  • H3K27me3缺失由H3 K27突变或EZHIP过表达介导。
  • EGFR抑制可能成为这类高度侵袭性胶质瘤的潜在治疗策略。

研究设计与样本

  • 研究纳入58例表观遗传学同质的恶性胶质瘤,富集儿童病例和丘脑位置,与已知儿童双丘脑胶质瘤亚型比较。

主要发现

  • EGFR基因扩增见于16/58(27%)肿瘤。
  • 30例有测序数据的肿瘤中,20例(67%)存在EGFR错义突变或小框内插入,其中5例合并EGFR扩增。
  • 30例中8例(27%)携带H3.1或H3.3 K27M突变,其中6例同时有EGFR改变。
  • 所有检测肿瘤均显示H3K27me3染色缺失,H3野生型病例中可见EZHIP过表达证据。
  • 部分肿瘤呈双丘脑生长模式,但相当比例位于单侧丘脑或其他(主要为中线)部位。

临床怎么用

  • 对儿童型丘脑胶质瘤应进行EGFR改变和H3K27me3状态检测以辅助分子分型。
  • EGFR抑制可作为该类高度侵袭性胶质瘤的潜在治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant astrocytic gliomas in children show a remarkable biological and clinical diversity. Small in-frame insertions or missense mutations in the epidermal growth factor receptor gene (EGFR) have recently been identified in a distinct subset of pediatric-type bithalamic gliomas with a unique DNA methylation pattern. METHODS: Here, we investigated an epigenetically homogeneous cohort of malignant gliomas (n = 58) distinct from other subtypes and enriched for pediatric cases and thalamic location, in comparison with this recently identified subtype of pediatric bithalamic gliomas. RESULTS: EGFR gene amplification was detected in 16/58 (27%) tumors, and missense mutations or small in-frame insertions in EGFR were found in 20/30 tumors with available sequencing data (67%; 5 of them co-occurring with EGFR amplification). Additionally, 8 of the 30 tumors (27%) harbored an H3.1 or H3.3 K27M mutation (6 of them with a concomitant EGFR alteration). All tumors tested showed loss of H3K27me3 staining, with evidence of overexpression of the EZH inhibitory protein (EZHIP) in the H3 wildtype cases. Although some tumors indeed showed a bithalamic growth pattern, a significant proportion of tumors occurred in the unilateral thalamus or in other (predominantly midline) locations. CONCLUSIONS: Our findings present a distinct molecular class of pediatric-type malignant gliomas largely overlapping with the recently reported bithalamic gliomas characterized by EGFR alteration, but additionally showing a broader spectrum of EGFR alterations and tumor localization. Global H3K27me3 loss in this group appears to be mediated by either H3 K27 mutation or EZHIP overexpression. EGFR inhibition may represent a potential therapeutic strategy in these highly aggressive gliomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sievers P, Sill M, Schrimpf D, et al. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro Oncol. 2021. PMID: 33130881. doi:10.1093/neuonc/noaa251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。